Acer Medical, a subsidiary of the Acer Group, is joining forces with Intel to aggressively expand its footprint in the AI smart healthcare market. The company announced that its AI-assisted diagnostic software, powered by Intel’s hardware and software technologies, can deliver accurate diagnostic results within seconds. Currently, three of its solutions have been deployed across more than 13 countries, including Taiwan, Thailand, Malaysia, and Indonesia.

With the deepening of its collaboration with Intel, market observers are optimistic that Acer Medical’s AI healthcare solutions will further expand their market reach.

Intel stated that Acer Medical’s AI-assisted software VeriSee DR supports the diagnosis of diabetic retinopathy, while VeriSee AMD aids in the screening of age-related macular degeneration. The results from these tools are processed and stored entirely offline using Acer laptops equipped with Intel Core Ultra processors.

Acer Medical aims to bring AI inference technology to the front lines where it is needed most, advancing AI medical imaging adoption in major institutions such as National Taiwan University Hospital, which has over 7,500 healthcare professionals.

In addition to VeriSee DR and VeriSee AMD, Acer Medical also provides VeriOsteo OP, an AI screening software for detecting abnormal bone mineral density, which has received approval from Taiwan’s Food and Drug Administration (TFDA).

All three solutions integrate Intel’s hardware and software—including Intel Core Ultra processors and the OpenVINO toolkit—with Acer Medical’s proprietary algorithms.

Chairman Allen Lien noted that by leveraging OpenVINO, software boot times were reduced by 70%, image analysis time by 90%, and memory usage by 90%. These AI solutions enable rapid screening for ophthalmic diseases and bone density abnormalities, helping hospitals and physicians enhance screening accuracy and speed, and allowing for earlier medical intervention.

Resource: 宏碁智醫強攻智慧醫療